Escherichia coli resistant strains are very sensitive to fosfomycin trometamol

Escherichia coli is the microorganism most often excreted in uncomplicated lower urinary tract infections. Due to the increased resistance of E.coli strains to quinolones, there is a need for alternative drugs for the treatment of infections caused by this pathogen.

Due to its specific microbiological and pharmacokinetic properties, fosfomycin trometamol is the most commonly used alternative drug among the large number of antibiotics available today. Italian researchers have determined the sensitivity of in vitro to phosphomycin tromethamol from 79 strains resistant to quinolones from E.coli isolated in clinics in the cities of Genoa and Parma, in comparison with amoxicillin, chloramphenicol, cotrimoxazole, cotilmicicin nitrofurantoin and tetracycline.

Fosfomycin trometamol showed the highest activity against strains of E. coli with MPC90 equal to 4 mg / L.

The study did not find E. coli strains resistant to fosfomycin trometamol, while 83.5%, 63.3%, 58.2% and 48.1% of micro- organisms were resistant to tetracycline, amoxicillin, chloramphenicol and cotrimoxazole, respectively. Resistance to nitrofurantoin and netilmicin was 12.7% and 6.3%, respectively.

In conclusion, it can be said that fosfomycin trometamol remains active against quinolone-resistant strains of E.coli, and the phenomenon of cross-resistance with other classes of antibacterial drugs is not a problem. real today.